Lipum AB (publ) has decided to postpone the interim report Q2 2025 to August 28, 2025
1 augusti, 15:00
1 augusti, 15:00
The previously announced publication date for the interim report Q2 2025 was August 14. The publication has now been postponed to August 28, 2025.
Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se
About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.
Attachments
Lipum AB (publ) has decided to postpone the interim report Q2 2025 to August 28, 2025
1 augusti, 15:00
The previously announced publication date for the interim report Q2 2025 was August 14. The publication has now been postponed to August 28, 2025.
Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se
About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.
Attachments
Lipum AB (publ) has decided to postpone the interim report Q2 2025 to August 28, 2025
Fonder
Konjunktur
Novo Nordisk
Aktieråd
Analys
Fonder
Konjunktur
Novo Nordisk
Aktieråd
Analys
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 566,53